TQB2928 injection

DRUG3 trials

Sponsors

Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

Conditions

Advanced CancerAdvanced Malignant NeoplasmAdvanced Solid Tumors and Hematological Malignancies

Phase 1

Phase 1 Trial of the TQB2928 Injection in Patients With Advanced Cancers

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Advanced Solid Tumors and Hematological Malignancies

Start: 2021-08-01End: 2022-12-01Target: 20Updated: 2021-04-22

Clinical Trial of the TQB2928 Injection in Patients With Advanced Cancers

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.Advanced Cancer

Start: 2022-01-24End: 2025-01-31Target: 180Updated: 2022-03-03

TQB2928 Injection Combined With Penpulimab in Treatment of Advanced Malignant Tumors.

TerminatedNCT06297642

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Advanced Malignant Neoplasm

Start: 2024-05-24End: 2024-07-31Updated: 2024-08-06